Sanofi Pasteur, A Sanofi Company

This early-stage study tested a new mRNA vaccine designed to protect against COVID-19. It involved 182 healthy adults and aimed to see if the vaccine was safe and if it triggered a strong immune response against the virus. Researchers tracked participants for about a year to moni…

This study aimed to compare a new type of flu vaccine made without using eggs to the standard egg-based flu vaccine in children aged 3 to 8 years. Researchers tested whether the new vaccine triggered a similar immune response and was as safe as the traditional vaccine. The trial …

This study tested a new vaccine designed to protect infants and toddlers from Respiratory Syncytial Virus (RSV). Researchers wanted to see if giving this RSV vaccine at the same time as a child's regular 6-month and 12-month shots would make the RSV vaccine less effective. The st…

This study aimed to see if a high-dose flu vaccine works better than the standard-dose vaccine at preventing the flu in very young children, aged 6 months to 3 years. It compared how many children in each group got lab-confirmed influenza and measured the body's immune response t…

This large study tested a new nasal spray vaccine designed to protect infants and toddlers from Respiratory Syncytial Virus (RSV), a common cause of serious lung infections. About 6,300 healthy children, aged 6 months to under 2 years, received either the vaccine or a placebo spr…

This early-stage study aimed to test the safety and immune response of a new investigational vaccine designed to protect against Meningitis B, a serious bacterial infection. It involved 576 healthy volunteers, including infants, toddlers, adolescents, and adults, comparing the ne…

This study tested a new nasal spray vaccine designed to protect infants and toddlers from Respiratory Syncytial Virus (RSV), a common cause of severe lung infections in young children. It involved about 950 healthy children aged 6 months to under 2 years old. The main goals were …

This study aimed to see if a high-dose flu vaccine works better than a standard-dose vaccine at preventing serious health problems in adults aged 65 and older. Over 33,000 participants received one of the two vaccines. Researchers then tracked hospitalizations and other health ev…